CRISPR Therapeutics Financials
| 1CG Stock | 40.80 0.00 0.00% |
CRISPR |
Understanding current and past CRISPR Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CRISPR Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in CRISPR Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in CRISPR Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CRISPR Therapeutics AG. Check CRISPR Therapeutics' Beneish M Score to see the likelihood of CRISPR Therapeutics' management manipulating its earnings.
| Foreign Associate | Germany |
| Instrument | Germany Stock View All |
| Exchange | Stuttgart Exchange |
| ISIN | CH0334081137 |
| Benchmark | Dow Jones Industrial |
CRISPR Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CRISPR Therapeutics's current stock value. Our valuation model uses many indicators to compare CRISPR Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CRISPR Therapeutics competition to find correlations between indicators driving CRISPR Therapeutics's intrinsic value. More Info.CRISPR Therapeutics AG is rated third in current valuation category among its peers. It is number one stock in price to book category among its peers . The ratio of Current Valuation to Price To Book for CRISPR Therapeutics AG is about 323,825,109 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CRISPR Therapeutics' earnings, one of the primary drivers of an investment's value.CRISPR Therapeutics Systematic Risk
CRISPR Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. CRISPR Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on CRISPR Therapeutics correlated with the market. If Beta is less than 0 CRISPR Therapeutics generally moves in the opposite direction as compared to the market. If CRISPR Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one CRISPR Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of CRISPR Therapeutics is generally in the same direction as the market. If Beta > 1 CRISPR Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
CRISPR Therapeutics Thematic Clasifications
CRISPR Therapeutics AG is part of ISP investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Internet Service Providers. Internet Service Providers (ISP) companies and IT providers specializing in internet technologies
This theme covers Internet Service Providers. Internet Service Providers (ISP) companies and IT providers specializing in internet technologies. Get More Thematic Ideas
| ISP | View |
Additional Tools for CRISPR Stock Analysis
When running CRISPR Therapeutics' price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.